Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating how well LY3537021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy in adults with cancer. This phase 2 study compares LY3537021 with a placebo, both given along with standard anti-nausea medicines. The study focuses on adults who have not previously received chemotherapy and are planned to receive specific types of chemotherapy drugs. Participants receive either LY3537021 or placebo as a subcutaneous injection before chemotherapy, along with standard antiemetic treatments taken by mouth, intravenously, or through skin patches, depending on local guidelines. The chemotherapy drugs used include cisplatin or anthracycline with cyclophosphamide administered intravenously. The study uses a double-blind and randomized design to compare the two groups. Throughout the study, participants are monitored for nausea and vomiting during the period from the start of chemotherapy through 120 hours after the first infusion. Researchers assess the proportion of participants who have a complete response, meaning no vomiting and no need for additional rescue medication, particularly in the delayed phase. Participants remain in the study for about two months until all parts are completed, including safety evaluations and pharmacokinetic measurements.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pumitamig combined with chemotherapy compared to bevacizumab combined with chemotherapy in adults with previously untreated, unresectable, or metastatic colorectal cancer. This phase 23 study aims to provide important information on treatment options for this type of advanced colorectal cancer. Participants will receive different combinations of study drugs, including pumitamig or bevacizumab, along with chemotherapy regimens such as FOLFOX, FOLFIRI, or CAPOX. The dosages are specified and given on designated days. The study uses a randomized, double-blind design to compare these treatments across multiple groups. During the study, participants will be closely monitored for tumor response, progression-free survival, and overall survival for up to five years. Evaluations include tumor measurements using RECIST criteria, safety assessments, and other clinical tests. This long-term follow-up helps researchers understand how well the treatments work and their effects over time.
Actively Recruiting
Researchers are evaluating a new medicine called Sofetabart Mipitecan Sofe-M in a three-part clinical trial for people with certain types of ovarian, peritoneal, and fallopian tube cancers. The study focuses on patients with platinum-resistant cancer, whose disease worsened during or within six months after platinum chemotherapy, and those with platinum-sensitive cancer, whose disease remained controlled for at least six months after platinum treatment. The trial aims to determine if Sofe-M is more effective and to better understand its safety compared to standard treatments. Participants receive different treatments depending on their group. In Part A, patients with platinum-resistant disease receive Sofetabart Mipitecan or chemotherapy or Mirvetuximab Soravtansine, all given intravenously. In Parts B and C, patients with platinum-sensitive disease receive Sofetabart Mipitecan plus Bevacizumab or platinum-based chemotherapy plus Bevacizumab, also administered intravenously. The choice of chemotherapy is made by the investigator. Treatments are given in parallel groups. During the study, participants undergo regular assessments including imaging scans to monitor disease progression, safety evaluations, and quality of life questionnaires. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, symptom changes, and drug levels in the blood. Each participants time in the study varies based on their response to treatment, with follow-up continuing up to 70 months after randomization to track outcomes and safety.
Actively Recruiting
Researchers are evaluating the long-term effects of lidocaine infusions given during and after surgery to reduce moderate or severe chronic post-surgical pain in adult women undergoing elective breast cancer surgery. This large, international, randomized, double-blind trial aims to detect a meaningful reduction in chronic pain one year after surgery and also assesses safety, pain relief, opioid use, nerve-related pain symptoms, psychological health, and quality of life. Participants receive either a lidocaine infusion starting with an intravenous bolus after anesthesia induction, continuing with an intraoperative intravenous infusion, and followed by a post-operative subcutaneous infusion for up to 24 hours. The lidocaine dosing is adjusted by lean body weight with a cap, while the comparison group receives a saline placebo infusion following the same schedule. Day-case surgeries receive only the intraoperative treatments without the post-operative infusion. During the trial, participants will be monitored for pain severity, opioid consumption, nerve-related symptoms, psychological distress, physical functioning, quality of life, safety events, and health care costs up to one year after surgery. The primary outcome is the incidence of moderate or severe chronic post-surgical pain reported at one year. Assessments include patient-reported outcomes, pain scores at 24 hours postoperatively, and opioid use at various timepoints. The total participation duration extends up to one year after surgery.
Actively Recruiting
The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.
Actively Recruiting
Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.
Actively Recruiting
Researchers are studying participants with chronic Venous Leg Ulcers VLUs to see if adding TR987 0.1% gel to the Standard of Care improves healing compared to Standard of Care alone. This Phase 3, randomized, double-blind trial aims to evaluate the effectiveness and safety of the TR987 gel in treating VLUs, a type of non-healing wound caused by venous insufficiency. Participants will be assigned to one of two groups one group will receive TR987 0.1% gel applied topically along with Standard of Care treatments like wound cleansing, dressings, and compression bandaging the other group will receive Standard of Care alone. Treatments will be applied twice weekly for the first four weeks, then once weekly for the following 12 weeks, totaling up to 16 weeks of treatment. During the study, participants will have their target ulcer monitored for complete closure at various time points, including the 12- and 16-week marks, as well as follow-up at three months after closure. Pain levels and changes in ulcer size will also be assessed. Safety and tolerability will be tracked throughout the trial. Participation involves regular visits for treatment and evaluation over the 16-week treatment period, with additional follow-up to assess lasting ulcer closure.